Anavex Life Sciences Corp. (NASDAQ:AVXL) keeps its position active in street, shares closed at $4.23 with moves up of 13.40%. Anavex (AVXL) reported that a 57-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease patients for ANAVEX 2-73; study met both primary & secondary endpoints.
At 57 weeks, Alzheimer’s patients taking a daily oral dose between 10mg and 50mg, ANAVEX 2-73 was well tolerated. There were no clinically important treatment-related adverse events and no serious adverse events.Specifically, in comparison to historical control from a pooled placebo arm cohort study conducted by the Alzheimer Disease Cooperative Study Group in mild-to-moderate AD patients of comparable ages and MMSE baselines, over 12 month the ANAVEX 2-73 data shows a calculated treatment benefit of 1.8 points on the MMSE scale (p<0.016) and a calculated treatment benefit of 4 points on the ADCS-ADL score (p<0.019). Furthermore, the correlation was positive with all measured scores. While price to cash ratio remained 15.79.
Should investors bet on Anavex Life Sciences Corp. following this recent trend? Read Considerable Report Here
Amicus Therapeutics, Inc. (NASDAQ:FOLD) jumped up 3.24% during the previous trading session. Amicus Therapeutics announces ‘positive’ prelim data from a Phase 1/2 study to investigate ATB200/AT2221; ATB200/AT2221 safety data show no infusion-associated reactions following 100+ infusions (FOLD).
ATB200-02 Study – Preliminary Data Highlights in Initial ERT-Switch Patients, ATB200/AT2221 safety measures (n=9) showed: No serious adverse events (SAEs). AEs were generally mild and transient. No serious adverse events (SAEs). AEs were generally mild and transient. To date, ATB200/AT2221 has shown no infusion-associated reactions following 100+ infusions. Clinical PK profile through Week 14 was as predicted based on previously declared preclinical data (n=4).
Can investors take a chance on buying FOLD this week? Get Your Free Report Here
Stocks of Verisk Analytics, Inc. (NASDAQ:VRSK) appeared in active trade move, slightly up 0.06% to trade at $83.19 in last session with shares volume of 647749. Verisk Analytics (VRSK) reported that additional $500 mln share repurchase authorization. Scott Stephenson, chairman, president, and chief executive officer, commented, “Verisk’s strong financial position and free cash flow generation enable us to drive growth from internal investments in innovation and acquisitions while also returning capital to shareholders through our share repurchase program…Our strategy remains to use our capital allocation decisions to drive shareholder value over time, as we have done historically,” concluded Stephenson. To taking a short look on firm’s performance of margin, it showed a positive 29.10% in the net profit margin and in addition to its operating margin, which remained 38.00%.
Will Verisk Analytics, Inc. retains its glamour following this report? Find Inside Facts Here